Cybin develops psychedelic-based therapeutic treatments for mental health conditions. The company focuses on bringing innovative drug candidates to market.

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

COM:CYBIN

Cybin

Last Close

15.57

21/11 20:57

Market Cap

269.69M

Beta: -

Volume Today

31.80K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics